Richard A Morgan

USPTO Granted Patents = 46 (Patent Applications = 7)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 7)

Average Co-Inventor Count = 2.3

ph-index = 20

Forward Citations = 1,288(Granted Patents)

Location History:

Vienne, WV (US) (1996)
Vienna, WV (US) (1983 - 2009)
Elizabethtown, PA (US) (2010)
Columbia, MD (US) (2002 - 2022)
Center Harbor, NH (US) (2021 - 2024)

Company Filing History:

24 out of 16,338

E.i. Dupont De Nemours and Company

patents

20 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

5. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1983-2025

Loading Chart...

46 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12441778 - T cell receptors recognizing HLA-A1-restricted MAGE-A3 (2025-10-14),

2. 11879017 - Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer (2024-01-23),

3. 11306131 - T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage (2022-04-19),

4. 11124580 - Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer (2021-09-21),

5. 10864252 - Anti-SSX-2 T cell receptors and related materials and methods of use (2020-12-15),

6. 10570214 - Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer (2020-02-25),

7. 10407485 - Murine anti-NY-ESO-1 T cell receptors (2019-09-10),

8. 10143724 - Anti-SSX-2 T cell receptors and related materials and methods of use (2018-12-04),

9. 10087230 - Murine anti-NY-ESO-1 T cell receptors (2018-10-02),

10. 9688739 - T cell receptors and related materials and methods of use (2017-06-27),

11. 9624306 - Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer (2017-04-18),

12. 9487573 - Murine anti-NY-ESO-1 T cell receptors (2016-11-08),

13. 9345748 - Anti-SSX-2 T cell receptors and related materials and methods of use (2016-05-24),

14. 9266960 - Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer (2016-02-23),

15. 9128080 - Modified T cell receptors and related materials and methods (2015-09-08),

Title: The Innovative Journey of Richard A. Morgan

Introduction:

Richard A. Morgan, a visionary inventor hailing from Vienna, WV, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents:

Richard A. Morgan's latest patents include a cutting-edge software application for enhancing cybersecurity measures in financial institutions and a revolutionary medical device aimed at improving patient care in hospitals worldwide.

Career Highlights:

With over two decades of experience in the tech industry, Richard A. Morgan has a proven track record of developing innovative solutions to complex problems. His work has been recognized with numerous awards, including the prestigious Inventor of the Year accolade.

Collaborations:

Throughout his career, Richard A. Morgan has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work seamlessly in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion:

In conclusion, Richard A. Morgan's passion for innovation and his dedication to pushing the boundaries of technology have solidified his reputation as a pioneering inventor in the industry. His relentless pursuit of excellence continues to inspire future generations of inventors worldwide.

This text is generated by artificial intelligence and may not be accurate.